GBL 100Alternative Names: TB4SO; Thymosin beta 4 sulfoxide
Latest Information Update: 06 Apr 2011
At a glance
- Originator Grannus BioSciences
- Mechanism of Action Immunosuppressants; Neutrophil inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Psoriasis
Most Recent Events
- 06 Apr 2011 Discontinued - Phase-I for Psoriasis in United Kingdom (Topical)
- 20 Feb 2007 Phase-I clinical trials in Psoriasis in United Kingdom (Topical)